Proteomics International Laboratories Limited
Proteomics International Laboratories Limited (PIQ.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Proteomics International Laboratories Limited (PIQ.AX), covering cash flow, earnings, and balance sheets.
Proteomics International Laboratories Limited (PIQ.AX) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Proteomics International Laboratories Limited PIQ.AX financial performance.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $837375.00 | $2.66M | $541715.00 | $299202.00 |
| Cost of Revenue | $932435.00 | $1.11M | $3.69M | $4.03M |
| Gross Profit | -$95060.00 | $1.55M | -$3.15M | -$3.74M |
| Gross Profit Ratio | -$0.11 | $0.58 | -$5.81 | -$12.48 |
| R&D Expenses | $841922.00 | $1.06M | $773817.00 | $1.14M |
| SG&A Expenses | $3.78M | $3.62M | $861332.00 | $707518.00 |
| Operating Expenses | $4.62M | $4.68M | $785032.00 | $450148.00 |
| Total Costs & Expenses | $5.55M | $5.78M | $4.48M | $4.48M |
| Interest Income | $0.00 | $167765.00 | $114462.00 | $128802.00 |
| Interest Expense | $0.00 | $21645.00 | $1532.00 | $0.00 |
| Depreciation & Amortization | $355351.00 | $308970.00 | $317904.00 | $295731.00 |
| EBITDA | -$4.24M | -$2.50M | -$3.62M | -$3.76M |
| EBITDA Ratio | -$5.07 | -$0.94 | -$6.68 | -$13.000 |
| Operating Income | -$4.72M | -$3.13M | -$3.93M | -$4.19M |
| Operating Income Ratio | -$5.63 | -$1.18 | -$7.26 | -$13.99 |
| Other Income/Expenses (Net) | $6265.00 | -$1.70M | $288765.00 | -$1.09M |
| Income Before Tax | -$4.71M | -$4.82M | -$3.82M | -$4.05M |
| Income Before Tax Ratio | -$5.63 | -$1.81 | -$7.05 | -$13.55 |
| Income Tax Expense | -$208018.00 | -$2.16M | -$63891.00 | -$1.85M |
| Net Income | -$4.49M | -$2.62M | -$3.75M | -$2.15M |
| Net Income Ratio | -$5.36 | -$0.99 | -$6.93 | -$7.18 |
| EPS | -$0.03 | -$0.02 | -$0.03 | -$0.02 |
| Diluted EPS | -$0.03 | -$0.02 | -$0.03 | -$0.02 |
| Weighted Avg Shares Outstanding | $149.54M | $126.62M | $122.33M | $118.11M |
| Weighted Avg Shares Outstanding (Diluted) | $149.54M | $126.61M | $122.33M | $118.11M |
Financial performance has remained strong, with revenue growing from $299202.00 in Q4 2023 to $837375.00 in Q2 2025. Gross profit continued to perform well, with margins at -11% in the latest quarter. Operating income reached -$4.72M in Q2 2025, holding a steady -563% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$4.24M. Net income dropped to -$4.49M, keeping EPS at -$0.03. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan